0000000000988940

AUTHOR

Francesco Sica

0000-0002-7255-952x

showing 1 related works from this author

Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders

2019

Abstract Objective To evaluate disease activity according to rituximab (RTX) induction and maintenance regimens in a multicenter real-life dataset of NMOSD patients. Methods This is an observational-retrospective multicentre study including patients with NMOSD treated with RTX in 21 Italian and 1 Swiss centers. Demographics, relapse rate and adverse events over the follow-up were summarized taking into account induction strategy (two-1 g infusions at a 15-day interval (IND-A) vs. 375 mg/m2/week infusions for one month (IND-B)) and maintenance therapy (regimen A (M-A) with fixed time-points infusions vs. regimen B (M-B) based on cytofluorimetric driven reinfusion regimens, the least further …

AdultMalemedicine.medical_specialtyMultivariate analysisEfficacyOutcome and Process AssessmentSettore MED/2603 medical and health sciences0302 clinical medicineMaintenance therapyInternal medicinemedicineHumansImmunologic FactorsIn patient030212 general & internal medicineAdverse effectAgedRetrospective StudiesNeuromyelitis opticabusiness.industryMultiple sclerosisGeneral MedicineMiddle Agedmedicine.diseaseNeuromyelitis opticaHealth CareRegimenOutcome and Process Assessment Health CareNeurologyEfficacy Neuromyelitis optica RituximabRituximabFemaleNeurology (clinical)businessRituximab030217 neurology & neurosurgerymedicine.drugFollow-Up Studies
researchProduct